Apolipoprotein E4 (ApoE4) genotype and/or gender do not appear to predict a response to donepezil in patients with mild-to-moderate Alzheimer's disease

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1248, 2000-01, pp. : 14-14

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Rosiglitazone appears to improve cognition in patients with Alzheimer's disease who do not possess an ApoE4 gene variant

By  

Inpharma, Vol. 1, Iss. 1547, 2006-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

ApoE genotype influences the biological effect of donepezil on APP metabolism in Alzheimer disease: evidence from a peripheral model

By Borroni B.   Colciaghi F.   Pastorino L.   Archetti S.   Corsini P.   Cattabeni F.   Di Luca M.   Padovani A.  

European Neuropsychopharmacology, Vol. 12, Iss. 3, 2002-06 ,pp. : 195-200

Elsevier

Access to resources Recommend Favorite

Targeting ApoE4/ApoE receptor LRP1 in Alzheimer's disease

By Martiskainen Henna  

Expert Opinion on Therapeutic Targets, Vol. 17, Iss. 7, 2013-10 ,pp. : 781-794

Informa Healthcare

Access to resources Recommend Favorite

Donepezil is better tolerated than rivastigmine in mild-to-moderate Alzheimer's disease

By  

Inpharma, Vol. 1, Iss. 1258, 2000-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite

APOE e4 genotype and cigarette smoking in adults with normal cognition and mild cognitive impairment: a retrospective baseline analysis of a national dataset

By Kalapatapu Raj K.   Delucchi Kevin L.  

The American Journal of Drug and Alcohol Abuse, Vol. 39, Iss. 4, 2013-07 ,pp. : 219-226

Informa Healthcare

Access to resources Recommend Favorite